|
2691 |
Risk-stratified DMARD tapering feasible in RA, reduces costs Enthalten in PharmacoEconomics & outcomes news Bd. 781, 1.7.2017, Nr. 1, date:7.2017: 30
|
|
|
2692 |
Rituximab Enthalten in Reactions weekly Bd. 1645, 1.4.2017, Nr. 1, date:4.2017: 259
|
|
|
2693 |
Rituximab Enthalten in Reactions weekly Bd. 1677, 11.11.2017, Nr. 1, date:11.2017: 233
|
|
|
2694 |
Rituximab Enthalten in Reactions weekly Bd. 1634, 14.1.2017, Nr. 1, date:1.2017: 233
|
|
|
2695 |
Rituximab Enthalten in Reactions weekly Bd. 1666, 26.8.2017, Nr. 1, date:8.2017: 263
|
|
|
2696 |
Rituximab Enthalten in Reactions weekly Bd. 1671, 30.9.2017, Nr. 1, date:9.2017: 342
|
|
|
2697 |
Rituximab Enthalten in Reactions weekly Bd. 1645, 1.4.2017, Nr. 1, date:4.2017: 260
|
|
|
2698 |
Rituximab Enthalten in Reactions weekly Bd. 1672, 7.10.2017, Nr. 1, date:10.2017: 237
|
|
|
2699 |
Rituximab Enthalten in Reactions weekly Bd. 1665, 19.8.2017, Nr. 1, date:8.2017: 251
|
|
|
2700 |
Rituximab Enthalten in Reactions weekly Bd. 1654, 3.6.2017, Nr. 1, date:6.2017: 303
|
|